Cargando…

AB083. Does concomitant testosterone replacement improve the response of tadalafil 5 mg once daily in men with lower urinary tract symptoms?

OBJECTIVES: Recently, tadalafil was found to be effective for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Testosterone (T) regulates nitric oxide synthase and is necessary to achieve an optimum response to PDE5 inhibitors. In the present study, we de...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Nam Cheol, Park, Hyun Jun, Moon, Du Geon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842499/
http://dx.doi.org/10.21037/tau.2016.s083
_version_ 1782428529084858368
author Park, Nam Cheol
Park, Hyun Jun
Moon, Du Geon
author_facet Park, Nam Cheol
Park, Hyun Jun
Moon, Du Geon
author_sort Park, Nam Cheol
collection PubMed
description OBJECTIVES: Recently, tadalafil was found to be effective for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Testosterone (T) regulates nitric oxide synthase and is necessary to achieve an optimum response to PDE5 inhibitors. In the present study, we determined whether T replacement in men with low T levels receiving tadalafil to treat LUTS improved the response of tadalafil on LUTS. METHODS: The present 12-week study was a randomized parallel study of clinical outcomes in men aged ≥40 years with symptomatic BPH (IPSS ≥12), prostate volumes ≥30 mL, and testosterone levels less than 300 ng/dl. Eligible patients received a combination of tadalafil 5 mg once daily and placement of a transdermal gel containing 10 g T (n=44), or tadalafil alone (n=46). The primary outcomes were post-treatment IPSS, peak urinary flow rate, and post-void residual urine volume (PVR). Secondary outcomes were changes in IIEF-EF domain scores, Global Assessment Questionnaire (GAQ) scores, and Life Satisfaction Checklist (LSC) scores. RESULTS: The extent of IPSS improvement from baseline to 12 weeks was the same in both groups (tadalafil+T –5.2 vs. tadalafil –5.0; P=0.634). Also, the changes in Q(max) and PVR from baseline were very similar in both groups. However, the tadalafil+T group showed a significantly greater change from baseline in the IPSS storage subscore, the IPSS-QoL score, and the IIEF-EF domain score. The tadalafil+T group showed significantly greater improvements in GAQ and LSC scores, as compared to the tadalafil-only group. The adverse event profiles of each group were similar to those of previous reports. CONCLUSIONS: Tadalafil plus testosterone was superior to tadalafil alone in improving LUTS in men with BPH/LUTS and low testosterone levels. Further study is needed with more number of patients and longer duration study for support of present study.
format Online
Article
Text
id pubmed-4842499
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-48424992016-05-09 AB083. Does concomitant testosterone replacement improve the response of tadalafil 5 mg once daily in men with lower urinary tract symptoms? Park, Nam Cheol Park, Hyun Jun Moon, Du Geon Transl Androl Urol Poster Presentation OBJECTIVES: Recently, tadalafil was found to be effective for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Testosterone (T) regulates nitric oxide synthase and is necessary to achieve an optimum response to PDE5 inhibitors. In the present study, we determined whether T replacement in men with low T levels receiving tadalafil to treat LUTS improved the response of tadalafil on LUTS. METHODS: The present 12-week study was a randomized parallel study of clinical outcomes in men aged ≥40 years with symptomatic BPH (IPSS ≥12), prostate volumes ≥30 mL, and testosterone levels less than 300 ng/dl. Eligible patients received a combination of tadalafil 5 mg once daily and placement of a transdermal gel containing 10 g T (n=44), or tadalafil alone (n=46). The primary outcomes were post-treatment IPSS, peak urinary flow rate, and post-void residual urine volume (PVR). Secondary outcomes were changes in IIEF-EF domain scores, Global Assessment Questionnaire (GAQ) scores, and Life Satisfaction Checklist (LSC) scores. RESULTS: The extent of IPSS improvement from baseline to 12 weeks was the same in both groups (tadalafil+T –5.2 vs. tadalafil –5.0; P=0.634). Also, the changes in Q(max) and PVR from baseline were very similar in both groups. However, the tadalafil+T group showed a significantly greater change from baseline in the IPSS storage subscore, the IPSS-QoL score, and the IIEF-EF domain score. The tadalafil+T group showed significantly greater improvements in GAQ and LSC scores, as compared to the tadalafil-only group. The adverse event profiles of each group were similar to those of previous reports. CONCLUSIONS: Tadalafil plus testosterone was superior to tadalafil alone in improving LUTS in men with BPH/LUTS and low testosterone levels. Further study is needed with more number of patients and longer duration study for support of present study. AME Publishing Company 2016-04 /pmc/articles/PMC4842499/ http://dx.doi.org/10.21037/tau.2016.s083 Text en 2016 Translational Andrology and Urology. All rights reserved.
spellingShingle Poster Presentation
Park, Nam Cheol
Park, Hyun Jun
Moon, Du Geon
AB083. Does concomitant testosterone replacement improve the response of tadalafil 5 mg once daily in men with lower urinary tract symptoms?
title AB083. Does concomitant testosterone replacement improve the response of tadalafil 5 mg once daily in men with lower urinary tract symptoms?
title_full AB083. Does concomitant testosterone replacement improve the response of tadalafil 5 mg once daily in men with lower urinary tract symptoms?
title_fullStr AB083. Does concomitant testosterone replacement improve the response of tadalafil 5 mg once daily in men with lower urinary tract symptoms?
title_full_unstemmed AB083. Does concomitant testosterone replacement improve the response of tadalafil 5 mg once daily in men with lower urinary tract symptoms?
title_short AB083. Does concomitant testosterone replacement improve the response of tadalafil 5 mg once daily in men with lower urinary tract symptoms?
title_sort ab083. does concomitant testosterone replacement improve the response of tadalafil 5 mg once daily in men with lower urinary tract symptoms?
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842499/
http://dx.doi.org/10.21037/tau.2016.s083
work_keys_str_mv AT parknamcheol ab083doesconcomitanttestosteronereplacementimprovetheresponseoftadalafil5mgoncedailyinmenwithlowerurinarytractsymptoms
AT parkhyunjun ab083doesconcomitanttestosteronereplacementimprovetheresponseoftadalafil5mgoncedailyinmenwithlowerurinarytractsymptoms
AT moondugeon ab083doesconcomitanttestosteronereplacementimprovetheresponseoftadalafil5mgoncedailyinmenwithlowerurinarytractsymptoms